CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support
CompanyDrug

CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support

Innovent Biologics' Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment
CompanyDrug

Innovent Biologics’ Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment

MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System
CompanyMedical Device

MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System

Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO
Company

Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO

YolTech Therapeutics' YOLT-201 Advances in ATTR Treatment Clinical Trial
CompanyDrug

YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial

Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation
CompanyDeals

Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation

Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceutical for Prescription Drug Co-Marketing
CompanyDeals

Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing

Boston Scientific's Next-Gen IVUS System AVVIGO+ Approved by China's NMPA for Coronary Disease Use
CompanyMedical Device

Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use

Guardant Health and Boehr Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic
CompanyDeals

Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic

Roche's Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson's Disease
CompanyDrug

Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease

Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments
CompanyDeals

Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments

Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China
CompanyDrug

Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China